DCOY
Decoy Therapeutics Inc.
Next earnings Aug 10, 2026
$5.52
▼ -6.76%$5.52▼ -97.08%
over 1Y
L $4.41EODHDH $216.00
Earnings Dividend Split Congress buy Congress sellGrouped by date · hover a pin to expand
Today-6.8%
1W-12.4%
1M-31.5%
3M-12.4%
YTD-29.5%
1Y-97.1%
Sell
Conviction
Horizon
Medium (3–12mo)
Street · 6 analysts
Sell
Conservative balance sheet (liabilities/equity 0.88x); but revenue fell -100.0% YoY.
Revenue (FY2022) $0.00 · FY2022
Decoy Therapeutics Inc. shows $0.00 in FY2022 revenue (-100.0% YoY), and -212.6% ROE.
Financials · annual, by fiscal year
| Line item | FY21 | FY22 | FY23 | FY24 | FY25 |
|---|---|---|---|---|---|
| Revenue | $1.84M | $0.00 | — | — | — |
| Gross profit | — | — | — | — | — |
| Operating income | -$12.8M | -$31.8M | -$12.9M | -$5.73M | -$12.6M |
| Net income | -$12.8M | -$31.6M | -$12.5M | -$5.58M | -$12.5M |
| Diluted EPS | -$7.72 | -$14.88 | -$30.74 | -$69.54 | -$129.10 |
| Net margin | -693.8% | — | — | — | — |
Annual figures from SEC 10-K XBRL filings. Open the filing links below for full statement detail.
Key statistics
Valuation
Enterprise value-$7.77M
EV / EBITDA—
EV / Sales—
EV / FCF—
P / FCF—
PEG (trailing)—
Earnings yield-426.5%
FCF yield-184.1%
Quality & risk
ROIC (est.)-169.2%
Free cash flow-$5.40M
Total debt—
Net cash$10.7M
Altman Z-Score-14.75 distress
Piotroski F-Score4/7
Capital returns
Buyback yield—
Dividend yield (est.)0.0%
Shareholder yield0.0%
Shares Δ YoY-69.5%
Computed from SEC XBRL annual figures + the current quote. EV and ROIC use long-term + current debt where filed; estimates, not investment advice.
Disclosure timeline
SEC · 8-Ks + reportsRed flag in recent filings — restated periodic report (2026-04-30). Worth a closer look.
Recent filings
all on EDGAR ↗EFFECTFiling2026-06-24open ↗S-1Filing2026-06-15open ↗RWFiling2026-06-05open ↗DEFA14AFiling2026-06-04open ↗DEF 14APeriod ending 2026-06-042026-06-04open ↗8-KPeriod ending 2026-05-192026-05-19open ↗10-QPeriod ending 2026-03-312026-05-08open ↗10-K/APeriod ending 2025-12-312026-04-30open ↗S-8Filing2026-04-02open ↗8-KPeriod ending 2026-03-312026-04-02open ↗10-KPeriod ending 2025-12-312026-03-31open ↗8-KPeriod ending 2026-03-052026-03-05open ↗
Frequently asked
- Is Decoy Therapeutics Inc. (DCOY) a buy?
- DCOY currently carries a Sell rating with 3/5 conviction, derived from its latest SEC filings. Conservative balance sheet (liabilities/equity 0.88x); but revenue fell -100.0% YoY.
- What is Decoy Therapeutics Inc.'s quality score?
- DCOY scores 34.641025641025635/100 (grade F) on a SEC-grounded quality model spanning value, growth, profitability, financial health and momentum.
Sources: SEC EDGAR (CIK 0001615219, latest 10-Q filed 2026-05-08) · EODHD · as of 6/23/2026, 12:43:13 AM.
Research and education only — not financial advice. EDGAR is not a registered investment adviser or broker-dealer and gives no personalized advice. Every call is impersonal — identical for all users, generated on a schedule from SEC filings plus a delayed/third-party price feed — may be wrong or out of date, and is not a recommendation to buy or sell any security. The operator and an affiliated trading operation may hold or trade the securities EDGAR rates; see Disclosures. Past performance does not guarantee future results. Do your own research.